A Phase 1 interventional study of AMG 510 in Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation, sponsored by Amgen. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be enrolled and will receive AMG 510 PO QD.
Drug: AMG 510
Subjects will be enrolled and will receive AMG 510 PO QD.
Number of Participants With Dose-limiting Toxicities (DLT)
DLTs were defined as any of the following adverse events (AEs) where a relationship to sotorasib could not be ruled out. Hematological toxicity * febrile neutropenia * neutropenic infection * grade 4 neutropenia * grade ≥ 3 thrombocytopenia for \> 7 days * grade 3 thrombocytopenia with grade ≥ 2 bleeding * grade 4 thrombocytopenia * grade 4 anemia. Non-hematological toxicity * grade ≥ 4 vomiting or diarrhea * grade 3 diarrhea or grade 3 vomiting lasting more than 3 days despite optimal medical support * grade ≥ 3 nausea for 3 days or more despite optimal medical support * any other grade ≥ 3 adverse event.
Time frame: Day 1 to Day 21
Number of Participants With Treatment-emergent AEs (TEAEs)
An AE was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE starting on or after first dose of study treatment. Treatment-related TEAEs were any TEAEs considered related to investigational product by the investigator. If relationship was missing, the event was assumed treatment-related. Clinically significant changes from the participant's baseline values in vital signs, 12-lead electrocardiograms, and clinical laboratory safety tests were reported as AEs.
Time frame: Day 1 until the end of study (or primary data cut-off date for ongoing participants); median [min, max] duration was 5.57 [1.5, 13.7] months
Maximum Observed Plasma Concentration (Cmax) of Sotorasib
Pharmacokinetic (PK) parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8
Time to Achieve Cmax (Tmax) of Sotorasib
PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8
Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24h) of Sotorasib
PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.
Time frame: Pre-dose and 0.25, 0.5, 1, 2, 4, 6, and 24 hours post-dose on Days 1 and 8
Objective Response (OR)
Measured by computed tomography (CT) or magnetic resonance imaging (MRI). Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.
Time frame: Day 1 until the end of study (approximately 12 months)
Duration of Response (DoR)
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Time frame: Day 1 until the end of study (approximately 12 months)
Progression-free Survival (PFS)
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Time frame: Day 1 until the end of study (approximately 12 months)
Disease Control Rate (DCR)
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Time frame: Day 1 until the end of study (approximately 12 months)
Time to Response (TTR)
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Time frame: Day 1 until the end of study (approximately 12 months)
Duration of Stable Disease
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Time frame: Day 1 until the end of study (approximately 12 months)
A total of 12 participants were enrolled in the study in Hong Kong and Taiwan. The study is currently ongoing; results are reported up to the primary data cut-off date of 31 December 2021.
| Milestone | Sotorasib |
|---|---|
| Started | 12 |
| Completed | 6 |
| Not completed | 6 |
| Withdrew: Participants continuing study | 4 |
| Withdrew: Death | 2 |
DLTs were defined as any of the following adverse events (AEs) where a relationship to sotorasib could not be ruled out. Hematological toxicity * febrile neutropenia * neutropenic infection * grade 4 neutropenia * grade ≥ 3 thrombocytopenia for \> 7 days * grade 3 thrombocytopenia with grade ≥ 2 bleeding * grade 4 thrombocytopenia * grade 4 anemia. Non-hematological toxicity * grade ≥ 4 vomiting or diarrhea * grade 3 diarrhea or grade 3 vomiting lasting more than 3 days despite optimal medical support * grade ≥ 3 nausea for 3 days or more despite optimal medical support * any other grade ≥ 3 adverse event.
| Participants | Sotorasib |
|---|---|
| Number of Participants With Dose-limiting Toxicities (DLT) | 0 |
An AE was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. A TEAE was defined as an AE starting on or after first dose of study treatment. Treatment-related TEAEs were any TEAEs considered related to investigational product by the investigator. If relationship was missing, the event was assumed treatment-related. Clinically significant changes from the participant's baseline values in vital signs, 12-lead electrocardiograms, and clinical laboratory safety tests were reported as AEs.
| Participants | Sotorasib |
|---|---|
| Any TEAEs | 11 |
| Any Treatment-related TEAEs | 4 |
Pharmacokinetic (PK) parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.
| ng/mL | Sotorasib |
|---|---|
| Day 1 | 9010 ± 5200 |
| Day 8 | 6330 ± 3030 |
PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.
| hours | Sotorasib |
|---|---|
| Day 1 | 0.85 (0.50 to 6.00) |
| Day 8 | 0.96 (0.47 to 5.90) |
PK parameters were determined from the concentration-time profile using standard non-compartmental approaches and considering the profile over the complete sampling interval.
| hours*ng/mL | Sotorasib |
|---|---|
| Day 1 | 73200 ± 43700 |
| Day 8 | 37400 ± 32000 |
Measured by computed tomography (CT) or magnetic resonance imaging (MRI). Assessed per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.
Results for this outcome have not been posted.
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Results for this outcome have not been posted.
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Results for this outcome have not been posted.
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Results for this outcome have not been posted.
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Results for this outcome have not been posted.
Measured by CT or MRI. Assessed per RECIST version 1.1 guidelines.
Results for this outcome have not been posted.
Collected over Day 1 until the end of study (or primary data cut-off date for ongoing participants); median [min, max] duration was 5.57 [1.5, 13.7] months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sotorasib | 2/12 (16.7%) | 6/12 (50%) | 11/12 (91.7%) |
| Event | Sotorasib |
|---|---|
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/12 |
| IleusGastrointestinal disorders | 1/12 |
| PyrexiaGeneral disorders | 1/12 |
| PneumoniaInfections and infestations | 1/12 |
| Liver function test abnormalInvestigations | 1/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/12 |
| Spinal cord compressionNervous system disorders | 1/12 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/12 |
| Event | Sotorasib |
|---|---|
| ConstipationGastrointestinal disorders | 3/12 |
| GastritisGastrointestinal disorders | 2/12 |
| PneumoniaInfections and infestations | 2/12 |
| HypokalaemiaMetabolism and nutrition disorders | 2/12 |
| AnaemiaBlood and lymphatic system disorders | 1/12 |
| TachycardiaCardiac disorders | 1/12 |
| Adrenal insufficiencyEndocrine disorders | 1/12 |
| Euthyroid sick syndromeEndocrine disorders | 1/12 |
| Abdominal distensionGastrointestinal disorders | 1/12 |
| DiarrhoeaGastrointestinal disorders | 1/12 |
Safety analysis set: all enrolled participants who received at least 1 dose of sotorasib.
| Age, Continuous(years) | Sotorasib |
|---|---|
| Mean | 64.9 ± 13.3 |
| Sex: Female, Male(Participants) | Sotorasib |
|---|---|
| Female | 4 |
| Male | 8 |
| Ethnicity (NIH/OMB)(Participants) | Sotorasib |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Sotorasib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 12 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Apr 2020 to primary completion in Dec 2021, 20 months.
Results were first posted in Mar 2024, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotorasib